PTK2 and neoplasm: Glabridin inhibits FAK and Src activation, blocks the FAK/Src complex, and suppresses the AKT and RhoA pathways, reducing cancer cell migration and invasion. It also limits tumor angiogenesis by inhibiting vascular endothelial cell tube formation.